NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Brush J, Boyd K, Chappell F, et al. The Value of FDG Positron Emission Tomography/Computerised Tomography (PET/CT) in Pre-Operative Staging of Colorectal Cancer: A Systematic Review and Economic Evaluation. Southampton (UK): NIHR Journals Library; 2011 Sep. (Health Technology Assessment, No. 15.35.)

Cover of The Value of FDG Positron Emission Tomography/Computerised Tomography (PET/CT) in Pre-Operative Staging of Colorectal Cancer: A Systematic Review and Economic Evaluation

The Value of FDG Positron Emission Tomography/Computerised Tomography (PET/CT) in Pre-Operative Staging of Colorectal Cancer: A Systematic Review and Economic Evaluation.

Show details

Executive summary

Background

Worldwide, large bowel (colorectal) cancer (CRC) accounts for > 1 million cancers per year or 9% of all new cancer cases. In the UK, CRC is the third most common malignancy (behind lung and breast cancer), with 37,514 new cases registered in 2006, of which around two-thirds (23,384) were in the colon and one-third (14,130) in the rectum.

Treatment of cancers of the colon and rectum differ considerably, but surgical resection is the mainstay of treatment for curative intent. Particularly for rectal cancers, there are a variety of surgical options and combinations with pre-operative therapies including pre-operative radiotherapy or chemoradiotherapy (where both chemotherapy and radiotherapy are delivered together), all with various levels of morbidity and mortality risk. Surgery is also the main treatment with curative potential for recurrent and metastatic (mainly liver) disease. The presence of disease distant to the site of planned surgery affects type and timing of treatments. Together, this wide variation in presentations and extents of treatments underpins the rationale for accurate pre-operative staging.

Following surgical resection, there is a comprehensive assessment of the tumour, its invasion characteristics and its spread. This forms the basis of tumour ‘staging’. Over the past two decades, a number of diagnostic tools have entered clinical practice and now facilitate the process of pre-operative staging. A number of imaging modalities are used in the pre-operative staging of CRC, including computerised tomography (CT), magnetic resonance imaging (MRI), ultrasound imaging and positron emission tomography (PET).

This report examines the role of CT in combination with PET scanning (‘hybrid’ scan) in pre-operative staging for CRC. The literature contains reports on the use of PET scanning alone compared with other imaging modalities for staging CRC, but as this technology is no longer available, the present report is limited to the role of hybrid fluorine-18-deoxyglucose (FDG) PET/CT scanning.

Objectives

  • To conduct a systematic review of the diagnostic accuracy and therapeutic impact of FDG PET/CT for the pre-operative staging of primary, recurrent and metastatic cancer.
  • To undertake probabilistic decision-analytic modelling (using Monte Carlo simulation).
  • To conduct a value of information analysis to help inform whether or not there is potential worth in undertaking further research.

Methods

Data sources

For each aspect of the research – the systematic review and the economic evaluation – a database was assembled from a comprehensive search for published and unpublished studies, which included database searches, reference list searches and contact with experts. All databases were searched from their inception until May 2009 and included BIOSIS Previews; Cumulative Index to Nursing and Allied Health Literature; The Cochrane Library; EMBASE; GlobalHealth; Index to Theses; MEDLINE; metaRegister of Current Controlled Trials; UK Clinical Research Network; and Web of Science, including Conference Proceedings Citation Index. The software used was Reference Manager version 10 (Thomson Reuters, CA, USA).

In the systematic review no language restrictions were applied and non-English-language studies were read by individuals with language-specific reading skills. Prospective and retrospective patient series (diagnostic cohort) and randomised controlled trials (RCTs) were eligible for inclusion. Both consecutive series and series that are not explicitly reported as consecutive were included.

Adults with known or suspected primary cancer of the colon or rectum undergoing pre-operative staging prior to curative surgery in a secondary care setting with any stage of disease were eligible for inclusion. Studies solely in patients with anal cancer were excluded.

Studies using only integrated FDG PET/CT equipment with both contrast-enhanced and non-contrast-enhanced CT were considered eligible for inclusion and were compared with standard imaging tests including ultrasound, diagnostic CT, MRI and PET, alone or in combination. Histopathology of surgical resected specimens or biopsy is the gold standard for tests used in CRC pre-operative staging. However, some patients do not undergo surgical intervention if their disease is too advanced for curative management, and therefore composite reference standards including imaging tests and clinical follow-up are used.

Data extraction

Two reviewers extracted all data and applied the criteria independently and resolved disagreements by discussion. Data to populate 2 × 2 contingency tables consisting of the numbers of true positives, true negatives, false positives and false negatives using the studies' own definitions were extracted, as were data relating to changes in management. All 14 items from the Quality Assessment of Diagnostic Accuracy Studies checklist were used to assess the methodological quality of the included studies.

Data synthesis

The 2 × 2 tables for the patient-level data were used to calculate sensitivity and specificity with confidence intervals (CIs). Data were plotted graphically in forest plots.

For the economic evaluation, economic models were designed for each of the disease states: primary, recurrent and metastatic. These were developed and populated based on a variety of information sources (in particular published data sources) and literature, and in consultation with clinical experts.

Results

The review found 30 studies that met the eligibility criteria. Only a small number of data were available from two small studies evaluating the use of FDG PET/CT in primary CRC, and there is insufficient evidence to support its routine use at this time. For FDG PET/CT used for the detection of recurrent disease, data were identified from five retrospective studies from which a pooled sensitivity of 91% (95% CI 87% to 95%) and specificity of 91% (95% CI 85% to 95%) were observed. Pooled accuracy data from patients undergoing staging for suspected metastatic disease showed FDG PET/CT to have a pooled sensitivity of 91% (95% CI 87% to 94%) and specificity of 76% (95% CI 58% to 88%), but the poor quality of the studies means the validity of the data may be compromised by several biases. A complementary handsearch study did not yield any additional unique studies relevant to FDG PET/CT.

The economic evaluation found that the cost per correct diagnosis outcome for primary CRC based on the diagnostic test accuracy estimates used in the models favoured the conventional imaging modalities, as did the cost per quality-adjusted life-year (QALY) outcomes. The recurrent models found FDG PET/CT as an add-on device to have an incremental cost-effectiveness ratio (ICER) of £21,409 per QALY in the rectal model and £6189 per QALY in the colon model. The metastatic model produced an ICER of £21,434 per QALY. Considering the National Institute for Health and Clinical Excellence's monetary threshold of £20,000–30,000 per QALY, these ICERs can be considered to be cost-effective.

Conclusions

The systematic review found only a small amount of evidence to support the use of FDG PET/CT in the pre-operative staging of primary, recurrent and metastatic CRC, and although FDG PET/CT was shown to change patient management, the data are divergent and the quality of research is generally poor. None of the economic models reported cost savings, but the approach adopted was conservative in order to determine more reliable results given the lack of current information. FDG PET/CT as an add-on imaging device is cost-effective in the pre-operative staging of recurrent colon, recurrent rectal and metastatic disease but not primary colon or rectal cancers.

Implications for health care

There is uncertainty about the value of using FDG PET/CT in CRC clinical practice, and those practitioners who access this imaging technology should routinely collect data to enable audits of patient outcomes, including detection rates and any changes in management resulting from its use.

Implications for research

An RCT and concurrent economic evaluation is required to evaluate the therapeutic impact and cost-effectiveness of FDG PET/CT compared with conventional imaging (without FDG PET/CT) for the pre-operative staging of recurrent and metastatic CRC.

There is no value in undertaking further research in primary CRC unless FDG PET/CT technology improves, for example if contrast-enhanced PET/CT becomes available then there would be potential value in undertaking an RCT to evaluate the diagnostic test accuracy and cost-effectiveness of contrast-enhanced PET/CT as a replacement for contrast-enhanced CT imaging.

Funding

Funding for this study was provided by the National Institute for Health Research Health Technology Assessment programme.

© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK99928

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.7M)
  • Disable Glossary Links

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...